Article

Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization

Department of Dermatology, Beth Israel Medical Center and St. Luke's-Roosevelt Hospital Center, New York, NY, USA.
Pediatric Allergy and Immunology (Impact Factor: 3.38). 06/2013; 24(5). DOI: 10.1111/pai.12095
Source: PubMed

ABSTRACT Background
Atopic dermatitis (AD) is associated with multiple comorbid conditions, such as asthma and food allergy. We sought to determine the impact of eczema severity on the development of these disorders and other non-atopic comorbidities in AD. Methods
We used the 2007 National Survey of Children's Health, a prospective questionnaire-based study of a nationally representative sample of 91,642 children aged 0-17yr. Prevalence and severity of eczema, asthma, hay fever and food allergy, sleep impairment, healthcare utilization, recurrent ear infections, and visual and dental problems were determined. ResultsIn general, more severe eczema is correlated with poorer overall health, impaired sleep, and increased healthcare utilization, including seeing a specialist, compared with children with mild or moderate disease (Rao-Scott chi-squared test, p<0.0001). Severe eczema was associated with a higher prevalence of comorbid chronic health disorders, including asthma, hay fever, and food allergies (p<0.0001). In addition, the severity of eczema was directly related to the severity of the comorbidities. These associations remained significant in multivariate logistic regression models that included age, sex, and race/ethnicity. Severe eczema was also associated with recent dental problems, including bleeding gums (p<0.0001), toothache (p=0.0004), but not broken teeth (p=0.04) or tooth decay (p=0.13). Conclusions
These data indicate that severe eczema is associated with multiple comorbid chronic health disorders, impaired overall health, and increased healthcare utilization. Further, these data suggest that children with eczema are at risk of decreased oral health. Future studies are warranted to verify this novel association.

0 Bookmarks
 · 
75 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The Asthma Predictive Index (API) and persistent wheezing phenotypes are associated with childhood asthma, but previous studies have not assessed their ability to predict objectively confirmed asthma. To determine whether the University of Cincinnati API Index (ucAPI) and/or persistent wheezing at age 3 can accurately predict objectively confirmed asthma at age 7. Data from the Cincinnati Childhood Allergy and Air Pollution Study, a high-risk prospective birth cohort, was used. Asthma was defined as parent-reported or physician-diagnosed asthma objectively confirmed by a change in FEV1 of ≥12% after bronchodilator or a positive methacholine challenge (PC20 ≤ 4 mg/mL); or as prior treatment with daily asthma controller medication(s). Multivariate logistic regression was used to investigate the relationship between confirmed asthma at age 7 and a positive ucAPI (adapted and modified from prior published API definitions) and persistent wheezing at age 3. At age 7, 103 of 589 children (17.5%) satisfied the criteria for asthma. Confirmed asthma at age 7 was significantly associated with a positive ucAPI (adjusted odds ratio [aOR] 13.3 [95% CI, 7.0-25.2]; P < .01) and the persistent wheezing phenotype (aOR 9.8 [95% CI, 4.9-19.5]; P < .01) at age 3. Allergic persistent wheezing was associated with a significantly higher risk of asthma (aOR 10.4 [95% CI, 4.1-26.0]; P < .01) than nonallergic persistent wheezing (aOR 5.4 [95% CI, 2.04-14.06]; P < .01). Both a positive ucAPI and persistent wheeze at age 3 were associated with objectively confirmed asthma at age 7; however, the highest risk was associated with ucAPI. These results demonstrate the ucAPI as a clinically useful tool for predicting future asthma in school-age children. Copyright © 2014 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
    11/2014; 2(6):709-715.e2. DOI:10.1016/j.jaip.2014.08.009
  • [Show abstract] [Hide abstract]
    ABSTRACT: Atopic dermatitis (AD) is the most common chronic inflammatory skin disorder in the USA and worldwide. There are significant differences in the epidemiology, phenotype, and genetics of AD in different racial and ethnic subgroups. In particular, patients of African descent have been found to have higher prevalence of AD in the USA and England, whereas Hispanic Americans have lower prevalence of AD. Further, African Americans have been found to have more severe disease and more comorbid allergic disorder. Patients of African descent appear to have different genetic risk factors, with less loss-of-function filaggrin 1 mutations and more filaggrin 2 mutations than patients of Northern or Eastern European origin. Finally, AD has different clinical phenotypes in African Americans, which clinicians need to recognize for the proper diagnosis and assessment of AD.
    01/2015; 4(1). DOI:10.1007/s13671-014-0097-7
  • [Show abstract] [Hide abstract]
    ABSTRACT: Atopic dermatitis (AD), named also atopic eczema, is a chronic relapsing inflammatory skin disease with a considerable social and economic burden. The primum movens of AD is in most cases a genetic and/or immune-supported defect of the skin barrier, facilitating penetration and sensitization to food or airborne allergens, as well as infections by S. aureus, herpes simplex virus or other microbes. New pathogenetic concepts have generated new approaches to prevention and therapy of AD. In particular, the daily use of emollients in newborns at high risk for AD has shown interesting results, with a reduction in the cumulative incidence of AD ranging from 32% to 50% of the treated infants. On the other hand, the AD preventive efficacy of food and/or inhalant allergen avoidance has been questioned, and supplementation strategies (vitamin D, probiotics or other compounds) need to be further investigated.This article is protected by copyright. All rights reserved.
    Pediatric Allergy and Immunology 11/2014; DOI:10.1111/pai.12309 · 3.38 Impact Factor